[go: up one dir, main page]

MX2017003359A - Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. - Google Patents

Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Info

Publication number
MX2017003359A
MX2017003359A MX2017003359A MX2017003359A MX2017003359A MX 2017003359 A MX2017003359 A MX 2017003359A MX 2017003359 A MX2017003359 A MX 2017003359A MX 2017003359 A MX2017003359 A MX 2017003359A MX 2017003359 A MX2017003359 A MX 2017003359A
Authority
MX
Mexico
Prior art keywords
protein kinase
activated
mitogen
inhibitors
protein
Prior art date
Application number
MX2017003359A
Other languages
English (en)
Other versions
MX373341B (es
Inventor
C Petter Russell
Niu Deqiang
david alexander Matthew
John Mcdonald Joseph
Ni Yike
Singh Juswinder
Chuaqui Claudio
MALONA John
Pabba Chittari
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2017003359A publication Critical patent/MX2017003359A/es
Publication of MX373341B publication Critical patent/MX373341B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona compuestos, composiciones de los mismos y métodos para utilizarlos.
MX2017003359A 2014-09-17 2015-09-16 INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. MX373341B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
MX2017003359A true MX2017003359A (es) 2017-11-22
MX373341B MX373341B (es) 2020-05-26

Family

ID=55454109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003359A MX373341B (es) 2014-09-17 2015-09-16 INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS.
MX2020005213A MX2020005213A (es) 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020005213A MX2020005213A (es) 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Country Status (30)

Country Link
US (5) US9458175B2 (es)
EP (2) EP3912981A1 (es)
JP (3) JP6556225B2 (es)
KR (1) KR102457848B1 (es)
CN (1) CN106998692B (es)
AU (1) AU2015317741B2 (es)
BR (1) BR112017005266B1 (es)
CA (1) CA2961607C (es)
CL (1) CL2017000576A1 (es)
CO (1) CO2017003279A2 (es)
CY (1) CY1124215T1 (es)
DK (1) DK3193611T3 (es)
EA (1) EA037299B1 (es)
EC (1) ECSP17023281A (es)
ES (1) ES2874561T3 (es)
HR (1) HRP20210529T1 (es)
HU (1) HUE054347T2 (es)
IL (1) IL251051B (es)
LT (1) LT3193611T (es)
MA (1) MA40534B1 (es)
MX (2) MX373341B (es)
PL (1) PL3193611T3 (es)
PT (1) PT3193611T (es)
RS (1) RS62017B1 (es)
SA (1) SA517381115B1 (es)
SG (2) SG11201701861RA (es)
SI (1) SI3193611T1 (es)
SM (1) SMT202100311T1 (es)
TW (1) TWI744217B (es)
WO (1) WO2016044463A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014238443A1 (en) 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
SI3193611T1 (sl) 2014-09-17 2021-08-31 Celgene Car Llc Inhibitorji MK2 in njihove uporabe
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP2020514360A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
WO2018170203A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170201A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP7692353B2 (ja) * 2018-10-02 2025-06-13 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN115484956A (zh) * 2020-02-14 2022-12-16 萨克生物研究学院 使用ulk1/2抑制剂的单一疗法和联合疗法
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University Compositions and methods for the treatment of pancreatic cancer
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4244341A4 (en) * 2020-11-12 2025-01-15 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
CA3242679A1 (en) 2022-01-14 2023-07-20 Shanghai Hansoh Biomedical Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN120390642A (zh) * 2022-10-27 2025-07-29 百时美施贵宝公司 Mk2抑制剂及其用途
CN120676947A (zh) * 2023-02-07 2025-09-19 细胞基因公司 可用作mk2激酶降解剂的化合物和组合物
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
WO2025002076A1 (zh) * 2023-06-26 2025-01-02 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR067535A1 (es) 2007-07-16 2009-10-14 Novartis Ag Derivados de lactama tetraciclicos
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2742261T3 (es) * 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
WO2013124040A1 (en) 2012-02-22 2013-08-29 Merck Patent Gmbh Liquid crystalline medium
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2898421A4 (en) * 2012-09-24 2016-07-13 Claremont Speede CONTROLLED DATA ACCESS AND METHOD AND SYSTEM FOR CLEARING DATA THROUGH A MOBILE TRANSMITTER
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
AU2014238443A1 (en) * 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
SI3193611T1 (sl) 2014-09-17 2021-08-31 Celgene Car Llc Inhibitorji MK2 in njihove uporabe
JP2018502860A (ja) 2015-01-08 2018-02-01 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害ペプチド製剤
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
JP2020514360A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Also Published As

Publication number Publication date
BR112017005266A2 (pt) 2017-12-12
US20210053984A1 (en) 2021-02-25
WO2016044463A3 (en) 2016-09-01
CY1124215T1 (el) 2022-05-27
US10253040B1 (en) 2019-04-09
EP3193611B1 (en) 2021-03-24
SG10201902326XA (en) 2019-04-29
SA517381115B1 (ar) 2021-03-09
US10577380B2 (en) 2020-03-03
WO2016044463A2 (en) 2016-03-24
JP2017529367A (ja) 2017-10-05
EA037299B1 (ru) 2021-03-05
CA2961607A1 (en) 2016-03-24
RS62017B1 (sr) 2021-07-30
LT3193611T (lt) 2021-08-25
BR112017005266B1 (pt) 2022-11-01
AU2015317741B2 (en) 2020-01-16
SMT202100311T1 (it) 2021-07-12
US20170114073A1 (en) 2017-04-27
CN106998692B (zh) 2020-09-08
CN106998692A (zh) 2017-08-01
US9790235B2 (en) 2017-10-17
CA2961607C (en) 2023-03-28
US20160075720A1 (en) 2016-03-17
CO2017003279A2 (es) 2017-09-29
EP3193611A2 (en) 2017-07-26
MA40534A (fr) 2016-03-24
SG11201701861RA (en) 2017-04-27
US11584757B2 (en) 2023-02-21
MA40534B1 (fr) 2021-04-30
EA201790380A1 (ru) 2017-08-31
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US20190375762A1 (en) 2019-12-12
AU2015317741A1 (en) 2017-04-20
MX2020005213A (es) 2020-08-20
JP7375072B2 (ja) 2023-11-07
MX373341B (es) 2020-05-26
TWI744217B (zh) 2021-11-01
PT3193611T (pt) 2021-05-28
IL251051B (en) 2019-11-28
EP3193611A4 (en) 2018-02-28
SI3193611T1 (sl) 2021-08-31
ECSP17023281A (es) 2017-06-30
JP2022078315A (ja) 2022-05-24
PL3193611T3 (pl) 2021-10-04
TW201617351A (zh) 2016-05-16
NZ730603A (en) 2024-02-23
KR20170063734A (ko) 2017-06-08
IL251051A0 (en) 2017-04-30
JP6556225B2 (ja) 2019-08-07
US9458175B2 (en) 2016-10-04
CL2017000576A1 (es) 2017-12-01
KR102457848B1 (ko) 2022-10-25
DK3193611T3 (da) 2021-05-10
EP3912981A1 (en) 2021-11-24
JP2019194236A (ja) 2019-11-07
HUE054347T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
CO2019003154A2 (es) Anticuerpos anti-pd-1 y sus usos
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112019012343A2 (pt) anticorpos il-11ra
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016012880A (es) Cadena j modificada.
MX380146B (es) Inhibidores mk2 y usos de los mismos.
MX2016014555A (es) Composiciones novedosas, usos y metodos para hacerlas.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
BR112016023503A2 (pt) arranjo de pista
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
DOP2017000260A (es) Piroglutamato de vortioxetina
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
DK3752129T3 (da) Torasemidsammensætning til multiple anvendelser
DK3706710T3 (da) Formuleringer med forlænget frigivelse til intraartikulære anvendelser
IT201700016964A1 (it) Composizione per la tosse
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
EA201890727A1 (ru) Модуляторы взаимодействия сестрина-gator2 и их применение

Legal Events

Date Code Title Description
FG Grant or registration